Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Syndax Pharmaceuticals (SNDX) EPS (Basic) (2016 - 2020)

Syndax Pharmaceuticals (SNDX) has disclosed EPS (Basic) for 6 consecutive years, with -$0.44 as the latest value for Q4 2020.

  • For Q4 2020, EPS (Basic) changed 0.0% year-over-year to -$0.44; the TTM value through Sep 2021 reached -$0.44, up 76.6%, while the annual FY2025 figure was -$3.29, 11.56% up from the prior year.
  • EPS (Basic) hit -$0.44 in Q4 2020 for Syndax Pharmaceuticals, up from -$0.46 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $0.79 in Q1 2018 and bottomed at -$2.85 in Q1 2016.
  • Average EPS (Basic) over 5 years is -$0.53, with a median of -$0.47 recorded in 2016.
  • Year-over-year, EPS (Basic) surged 257.45% in 2018 and then crashed 167.09% in 2019.
  • Syndax Pharmaceuticals' EPS (Basic) stood at -$0.59 in 2016, then crashed by 35.59% to -$0.8 in 2017, then soared by 187.5% to $0.7 in 2018, then tumbled by 162.86% to -$0.44 in 2019, then changed by 0.0% to -$0.44 in 2020.
  • According to Business Quant data, EPS (Basic) over the past three periods came in at -$0.44, -$0.46, and -$0.42 for Q4 2020, Q3 2020, and Q2 2020 respectively.